GNC-077 / Biokin Pharma - LARVOL DELTA

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

New P1 trial • Gastrointestinal Cancer • Gastrointestinal Disorder • Oncology • Solid Tumor

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Breast Cancer • Oncology • Solid Tumor

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Metastases • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Baili Tianheng (688506.SH): GNC-077 multi-specific antibody injection for the treatment of advanced solid tumors received approval for Phase I clinical trial [Google translation] (Zhitong Finance) - "According to the Zhitong Finance APP, Baili Tianheng...announced that the company recently received the 'Notice of Approval for Drug Clinical Trial' officially approved and issued by the National Medical Products Administration (NMPA). The company's independently developed innovative biological drug multi-specific antibody GNC-077's clinical trial was approved."

New P1 trial • Oncology • Solid Tumor